These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27636721)

  • 1. Kinetic of Virologic Response to Pegylated Interferon and Ribavirin in Children With Chronic Hepatitis C Predicts the Effect of Treatment.
    Indolfi G; Nebbia G; Cananzi M; Maccabruni A; Zaramella M; D'Antiga L; Grisotto L; Azzari C; Resti M;
    Pediatr Infect Dis J; 2016 Dec; 35(12):1300-1303. PubMed ID: 27636721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
    Marcellin P; Cheinquer H; Curescu M; Dusheiko GM; Ferenci P; Horban A; Jensen D; Lengyel G; Mangia A; Ouzan D; Puoti M; Rodriguez-Torres M; Shiffman ML; Schmitz M; Tatsch F; Rizzetto M
    Hepatology; 2012 Dec; 56(6):2039-50. PubMed ID: 22706730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK
    J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
    J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
    Aghemo A; Rumi MG; De Nicola S; Colombo M
    Hepatology; 2010 Sep; 52(3):1170-1. PubMed ID: 20812363
    [No Abstract]   [Full Text] [Related]  

  • 7. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.
    Jain MK; Pasipanodya JG; Alder L; Lee WM; Gumbo T
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1115-20. PubMed ID: 23183434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C.
    Breilh D; Foucher J; Castéra L; Trimoulet P; Djabarouti S; Merrouche W; Couzigou P; Saux MC; de Lédinghen V
    Aliment Pharmacol Ther; 2009 Sep; 30(5):487-94. PubMed ID: 19523176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
    Roomer R; van Vuuren AJ; Schutten M; Heijens A; Janssen HL; de Knegt RJ
    Antivir Ther; 2011; 16(5):771-4. PubMed ID: 21817199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children.
    Pawłowska M; Pilarczyk M; Halota W
    Med Sci Monit; 2010 Dec; 16(12):CR616-21. PubMed ID: 21119580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.
    Frei P; Leucht AK; Held U; Kofmehl R; Manser CN; Schmitt J; Mertens J; Rau M; Baur K; Gerlach T; Negro F; Heim M; Moradpour D; Cerny A; Dufour JF; Müllhaupt B; Geier A;
    Liver Int; 2014 Apr; 34(4):551-7. PubMed ID: 24034338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
    World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC; Tran TT; Poordad FF
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
    Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C; Schwendy S; Möller B; Dikopoulos N; Buggisch P; Encke J; Teuber G; Goeser T; Thimme R; Klinker H; Boecher WO; Schulte-Frohlinde E; Prinzing R; Herrmann E; Zeuzem S; Berg T
    Gastroenterology; 2011 Nov; 141(5):1656-64. PubMed ID: 21784046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.